SCICLONE PHARMACEUTICALS INC
SCICLONE PHARMACEUTICALS INC (SCLN): 9 pipeline candidates · ~65 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
65.0 months
2% dilution
Lead: Phase 3
9 candidates
N/A
N/A
A transparent, data-derived signal for SCICLONE PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$157.3M
Quarterly Burn
$8.3M
Runway
65.0 mo
Revenue
$44.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
Frequently asked questions
How many drug candidates are in SCICLONE PHARMACEUTICALS INC's pipeline?
SCICLONE PHARMACEUTICALS INC (SCLN) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SCICLONE PHARMACEUTICALS INC's lead drug candidate?
SCICLONE PHARMACEUTICALS INC's most advanced tracked candidate is abtl-0812 (Phase 1) for solid tumors.
What is SCICLONE PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SCICLONE PHARMACEUTICALS INC has approximately 65.0 months of cash runway.
Who is the CEO of SCICLONE PHARMACEUTICALS INC?
Foster City is the chief executive officer of SCICLONE PHARMACEUTICALS INC (SCLN).
Get the full picture on SCICLONE PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.